{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:37:30Z","timestamp":1787017050030,"version":"build-2736575974"},"reference-count":24,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"unspecified","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2021,11,30]]},"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Soluble ST2 (sST2) reflects inflammation, endothelial dysfunction and myocardial fibrosis, is produced in the lungs and is an established biomarker in heart failure. We sought to determine the role of sST2 in COVID-19 by assessing pathophysiological correlates and its association to in-hospital outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We enrolled 123 consecutive, hospitalised patients with COVID-19 in the prospective, observational COVID-19 MECH study. Biobank samples were collected at baseline, day 3 and day 9. The key exposure variable was sST2, and the outcome was ICU treatment with mechanical ventilation or in-hospital death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Concentrations of sST2 at baseline was median 48 (IQR 37\u201367) ng\/mL, and 74% had elevated concentrations (&gt;37.9 ng\/mL). Higher baseline sST2 concentrations were associated with older age, male sex, white race, smoking, diabetes, hypertension and chronic kidney disease. Baseline sST2 also associated with the presence of SARS-CoV-2 viraemia, lower oxygen saturation, higher respiratory rate and increasing concentrations of biomarkers reflecting inflammation, thrombosis and cardiovascular disease. During the hospitalisation, 8 (7%) patients died and 27 (22%) survivors received intensive care unit (ICU) treatment. Baseline sST2 concentrations demonstrated a graded association with disease severity (median, IQR): medical ward 43 (36\u201359) ng\/mL; ICU 67 (39\u2013104) ng\/mL and non-survivors 107 (72\u2013116) ng\/mL (p&lt;0.001 for all comparisons). These associations persisted at day 3 and day 9 .<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>sST2 concentrations associate with SARS-CoV-2 viraemia, hypoxaemia and concentrations of inflammatory and cardiovascular biomarkers. There was a robust association between baseline sST2 and disease severity that was independent of, and superior to, established risk factors. sST2 reflects key pathophysiology and may be a promising biomarker in COVID-19.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04314232\">NCT04314232<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/openhrt-2021-001884","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T12:34:38Z","timestamp":1640090078000},"page":"e001884","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Soluble ST2 concentrations associate with in-hospital mortality and need for mechanical ventilation in unselected patients with COVID-19"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct04314232","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Torbjorn","family":"Omland","sequence":"first","affiliation":[{"name":"Department of Cardiology, Akershus University Hospital, Lorenskog, Norway"},{"name":"Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Prebensen","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Infectious Diseases, Akershus University Hospital, Lorenskog, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Jonassen","sequence":"additional","affiliation":[{"name":"Center for Laboratory Medicine, \u00d8stfold Hospital Trust, Gr\u00e5lum, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"My","family":"Svensson","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway"},{"name":"Division of Research and Innovation, Akershus University Hospital, L\u00f8renskog, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Erik","family":"Berdal","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Infectious Diseases, Akershus University Hospital, Lorenskog, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingebj\u00f8rg","family":"Seljeflot","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway"},{"name":"Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital Ullevaal, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5871-1804","authenticated-orcid":false,"given":"Peder Langeland","family":"Myhre","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Akershus University Hospital, Lorenskog, Norway"},{"name":"Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,12,21]]},"reference":[{"key":"2025081710012879000_8.2.e001884.1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0235653"},{"key":"2025081710012879000_8.2.e001884.2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41569-020-0413-9","article-title":"COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives","volume":"17","author":"Nishiga","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2025081710012879000_8.2.e001884.3","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvy166"},{"key":"2025081710012879000_8.2.e001884.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.01.044"},{"key":"2025081710012879000_8.2.e001884.5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005488"},{"key":"2025081710012879000_8.2.e001884.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.09.026"},{"key":"2025081710012879000_8.2.e001884.7","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfs006"},{"key":"2025081710012879000_8.2.e001884.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2017.02.034"},{"key":"2025081710012879000_8.2.e001884.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2013.10.005"},{"key":"2025081710012879000_8.2.e001884.10","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000509"},{"key":"2025081710012879000_8.2.e001884.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-010-1773-0"},{"key":"2025081710012879000_8.2.e001884.12","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqv082"},{"key":"2025081710012879000_8.2.e001884.13","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3182978f91"},{"key":"2025081710012879000_8.2.e001884.14","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1097\/CCM.0000000000001814","article-title":"Plasma concentrations of soluble suppression of Tumorigenicity-2 and interleukin-6 are predictive of successful liberation from mechanical ventilation in patients with the acute respiratory distress syndrome","volume":"44","author":"Alladina","year":"2016","journal-title":"Crit Care Med"},{"key":"2025081710012879000_8.2.e001884.15","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.120.050360","article-title":"Growth differentiation factor 15 provides prognostic information superior to established cardiovascular and inflammatory biomarkers in unselected patients hospitalized with COVID-19","volume":"142","author":"Myhre","year":"2020","journal-title":"Circulation"},{"key":"2025081710012879000_8.2.e001884.16","doi-asserted-by":"crossref","first-page":"e799","DOI":"10.1093\/cid\/ciaa1338","article-title":"Severe acute respiratory syndrome coronavirus 2 RNA in plasma is associated with intensive care unit admission and mortality in patients hospitalized with coronavirus disease 2019","volume":"73","author":"Prebensen","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025081710012879000_8.2.e001884.17","unstructured":"Critical Diagnostics . Instructions for use manual for the presage ELISA assay. Available: http:\/\/www.criticaldiagnostics.com\/OUS\/products\/pdfs\/Presage_ST2_CE_Assay_IFU.pdf"},{"key":"2025081710012879000_8.2.e001884.18","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780040112"},{"key":"2025081710012879000_8.2.e001884.19","doi-asserted-by":"crossref","unstructured":"Huang J . Comparing biomarkers for COVID-19 disease with commonly associated preexisting conditions and complications. medRxiv 2020:2020.10.02.20205609.","DOI":"10.1101\/2020.10.02.20205609"},{"key":"2025081710012879000_8.2.e001884.20","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics11020175","article-title":"The novel perspectives opened by ST2 in the pandemic: a review of its role in the diagnosis and prognosis of patients with heart failure and COVID-19","volume":"11","author":"Miftode","year":"2021","journal-title":"Diagnostics"},{"key":"2025081710012879000_8.2.e001884.21","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2217\/bmm-2020-0410","article-title":"Serum-Soluble ST2 as a novel biomarker reflecting inflammatory status and illness severity in patients with COVID-19","volume":"14","author":"Zeng","year":"2020","journal-title":"Biomark Med"},{"key":"2025081710012879000_8.2.e001884.22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-10894-x","article-title":"Interleukin-33 promotes inflammation-induced lymphangiogenesis via ST2\/TRAF6-mediated Akt\/eNOS\/NO signalling pathway","volume":"7","author":"Han","year":"2017","journal-title":"Sci Rep"},{"key":"2025081710012879000_8.2.e001884.23","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1169-6"},{"key":"2025081710012879000_8.2.e001884.24","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.120.314860"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2021-001884","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T17:01:34Z","timestamp":1755450094000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2021-001884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,12,21]]},"published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1136\/openhrt-2021-001884"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2021-001884","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]}}}